Cingulate Inc. (CING) Form 10-Q — Aug 13, 2026
Cingulate Inc. reported a Q2 2026 net loss of $5.9 million, up 17.8% from $5.0 million a year earlier, and a first-half net loss of $15.2 million versus $8.8 million in the prior-year period. The pre-revenue biopharmaceutical company ended the quarter with $28.4 million in cash and a $147.6 million accumulated deficit. The 10-Q discloses substantial doubt about the company's ability to continue as a going concern within one year.
Key figures
- Total Debt
- 5067293
- Total Assets
- 33066321
- Cash Position
- 28402819
- Shares Outstanding
- 14541826
- Cash runway
- into mid 2027
- Q2 2025 net loss
- 4983261
- Q2 2026 net loss
- 5870264
- Rd expense q2 2026
- 1486825
- Shares dec 31 2025
- 7250299
- Accumulated deficit
- 147557384
- Sga expense q2 2026
- 3928150
- Six month 2025 net loss
- 8835939
- Cumulative capital raised
- 160400000
- Shares issued june 30 2026
- 13894882
- Weighted avg shares q2 2026
- 13186057
- Operating loss six months 2026
- 13338197
- Shares outstanding aug 12 2026
- 14541826
- Net cash used in operating activities six months
- 12812465
Price after filing
1 day: +2.0%7 days: +6.8%30 days: +0.6%
Close on the filing date to close N calendar days later (from $4.99). Historical, not a forecast.
AI analysis
Red flags6 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.